Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Supernus Pharmaceuticals

Supernus Pharmaceuticals Stock Scores RS Rating Upgrade

A Relative Strength Rating upgrade for Supernus Pharmaceuticals shows improving technical performance.

Investors Business Daily

Stocks With Rising Relative Strength: Supernus Pharmaceuticals

Supernus Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics

Supernus Pharmaceuticals agreed Monday to buy beleaguered biotech Sage Therapeutics in a deal that bolsters its nonpsychiatric portfolio.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Supernus Pharmaceuticals Hits 80-Plus Relative Strength Rating Benchmark

A Relative Strength Rating upgrade for Supernus Pharmaceuticals shows improving technical performance.

Investors Business Daily

Supernus Pharmaceuticals Reaches 80-Plus Relative Strength Rating Benchmark

Supernus Pharmaceuticals sees its Relative Strength Rating move into the 80-plus level.

Investors Business Daily

Supernus Pharmaceuticals Meets 80-Plus Relative Strength Rating Benchmark

Supernus Pharmaceuticals sees its Relative Strength Rating hit the 80-plus level.

Investors Business Daily

3 Pharma Stocks to Anchor Your Portfolio

The pharma market is poised to thrive due to the continuous medicinal advancements to meet the escalating demand for chronic disease treatment, technological advancements, and increased research and development. Given this backdrop, quality pharma stocks Procaps Group S.A. (PROC), Supernus Pharmaceuticals (SUPN), and GSK plc (GSK) could be wise portfolio…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Rising Pharma Stocks to Consider Buying Now

The pharmaceutical sector is transforming due to the swift uptake of digital solutions and worldwide spending growth. Hence, fundamentally strong pharma stocks Supernus Pharmaceuticals (SUPN), Astellas Pharma (ALPMY), and Eli Lilly (LLY) might be solid buys now. Read more….

StockNews.com

Looking Into Supernus Pharmaceuticals's Return On Invested Capital

According to Benzinga Pro data Supernus Pharmaceuticals (NASDAQ:SUPN) posted a 88.67% decrease in earnings from Q3. Sales, however, increased by 7.13% over the previous quarter to $159.05 million.

Benzinga

Supernus Pharmaceuticals Stock Sees Relative Strength Rating Jump To 92

Supernus Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Investor Business Daily

Medical Pharmaceuticals

125 stories

Eli Lilly and Company

Supernus Pharmaceuticals

10 stories

SUPN

10 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.